RHYTHM PHARMACEUTICALS, INC. (RYTM) Financials
Annual revenue, profitability and per-share results for RHYTHM PHARMACEUTICALS, INC., as reported in SEC filings.
Revenue • FY2025
$189.76M
▲ 45.8%YoY
Net income • FY2025
-$196.54M
▲ 24.6%YoY
Gross margin • FY2025
89.7%
Diluted EPS • FY2025
$-3.11
▲ 28.3%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $189.76M | -$196.54M | $170.26M | $-3.11 | -$116.63M | -101.2% | +45.8% |
| FY2024 | $130.13M | -$260.6M | $116.76M | $-4.34 | — | -204.0% | +68.1% |
| FY2023 | $77.43M | -$184.68M | $68.13M | $-3.20 | -$136.2M | -238.1% | +227.6% |
| FY2022 | $23.64M | -$181.12M | $21.5M | $-3.47 | -$173.71M | -757.9% | +649.5% |
Figures as reported in RHYTHM PHARMACEUTICALS, INC.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Never miss a RYTM filing.
Get an email when RYTM files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.